Key clinical point: An autologous fecal transplant can restore intestinal microbiota after allogeneic hematopoietic stem cell transplant.
Major finding: All patients who received auto-FMT regained pre–allo-HSCT microbiota composition and diversity (P less than .0001).
Study details: An open-label study involving 25 allo-HSCT patients that compared auto-FMT with no treatment.
Disclosures: Study funding was provided by the Leonard Tow Foundation and the Memorial Sloan Kettering’s Center for Microbes, Inflammation, and Cancer. The authors reported disclosures related Merck, AbbVie, Nektar Therapeutics, Novartis, and others.
Taur Y et al. Sci Transl Med. 2018 Sep 26. doi: 10.1126/scitranslmed.aap9489.
This Week's Must Reads
Oncologists raise access concerns about new mobile technology, Article based on interviews.
Broad opioid legislation advances in Congress, Senate floor debate, Sept. 17, 2018
Early supportive care cuts costs related to curative treatment, Koprowski CD et al. 2018 ASCO Quality Care Symposium, Abstract 142
Employee deductibles outstrip wages, Kaiser Family Foundation, 2018 Employer Health Benefits
The financial burden of metastatic breast cancer, Wheeler SB et al. Quality Care Symposium, Abstract 32
Must Reads in Patient & Survivor Care
auto-FMT could help ease GVHD after transplant, Taur Y et al. Sci Transl Med. 2018 Sep 26. doi: 10.1126/scitranslmed.aap9489
Expansion in clinical trial eligibility requested by ASCO, Friends of Cancer and ASCO letter to the FDA
Promise of broad genomic testing of NSCLC disappoints in community oncology , Presley CJ et al. JAMA. 2018 Aug 7. doi: 10.1001/jama.2018.9824
Pregnancy does not increase melanoma recurrence risk, DiSano JA et al. J Surg Res. 2018 Jun 16. doi: 10.1016/j.jss.2018.05.026.
Lay health workers enhance care at end of life, Patel MI et al. JAMA Oncology. 2018 Jul 26. doi: 10.1001/jamaoncol.2018.2446.